The Efficacy of Doxazosin for Cocaine Users

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Doxazosin, an alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. This study will evaluate the effectiveness of doxazosin in preventing drug relapse among cocaine dependent participants.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baylor College of Medicine
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Adrenergic Antagonists; Cocaine; Doxazosin

Criteria

Inclusion Criteria:

• Meets DSM-IV diagnosis criteria for cocaine dependence, as determined by self-reported use of cocaine at least once weekly for at least 1 month prior to study entry; a positive urine test for cocaine; and a score greater than 3 on the Severity of Dependence Scale

• If female, willing to use contraception throughout the study

Exclusion Criteria:

• Meets DSM-IV diagnosis criteria for dependence on any drugs other than cocaine, or tobacco

• Current major psychiatric illness, including schizophrenia, bipolar disorder, or other psychotic disorder

• Current suicidal or homicidal ideation

• Current use of a prescribed psychotropic medication that cannot be discontinued

• History of or current major medical illness, including major heart, kidney, endocrine, or liver disorder; abnormal liver function (SGOT or SGPT levels three times greater than normal); or high blood pressure or low blood pressure

• High risk factor for heart disease, seizure disorders, or any illness for which disulfiram or methadone treatment would be inadvisable

• Currently taking metronidazole or clotrimazole

• Pregnant or breastfeeding